Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

248
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
04/24/2015 04/27/2015 04/28/2015 04/29/2015 04/30/2015 Date
99.8(c) 100.4(c) 99.55(c) 96.7(c) 96.65(c) Last
3 327 647 3 073 417 5 248 582 5 980 221 6 601 378 Volume
-0.80% +0.60% -0.85% -2.86% -0.05% Change
More quotes
Financials ($)
Sales 2015 52 607 M
EBIT 2015 13 083 M
Net income 2015 12 303 M
Debt 2015 6 219 M
Yield 2015 2,79%
Sales 2016 54 027 M
EBIT 2016 14 517 M
Net income 2016 11 027 M
Debt 2016 4 651 M
Yield 2016 2,85%
PER 2015 17,92
PER 2016 23,17
EV / Sales 2015 5,41x
EV / Sales 2016 5,24x
Capitalization 278 545 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers... 
Sector
Pharmaceuticals
Calendar
05/19Presentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
05/02 NOVARTIS : Manhattan U.S. Attorney Announces $60 Million Civil Fraud Settlement ..
05/01 Doubts grow over GlaxoSmithKline's 4 billion pound capital return plan
04/30 NOVARTIS : MILITARY $67,223 Federal Contract Awarded to Alcon Laboratories
04/30 NOVARTIS : CONTRACT AWARD - 65-- Novartis Vaccines and Diagnostics Award for Vac..
04/28 GENMAB A/S : Announces Phase III Study of Arzerra® Met Primary Endpoint of Impro..
04/27 NOVARTIS : announces Phase III study of Arzerra® met primary endpoint of improve..
04/27 NOVARTIS : announces Phase III study of Arzerra® met primary endpoint of improve..
04/24 NOVARTIS : Federal Contracts Awarded to Companies in New Jersey (April 24)
More news
Sector news : Pharmaceuticals - NEC
05:45aDJMyriad Genetics Fights Off Threats From Rivals
05/02 EXCLUSIVE - SIEMENS HEALTHCARE UNIT : sources
05/02 AMGEN : Lodi cancer survivor Kelsey Walters honored as Breakaway Champion in Amg..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/01 AbbVie Clearance Sale Going On Now
05/01 GILEAD PROVES GOLDEN : The Importance Of Its Beat-And-Raise Quarter
04/30 COMPETITORS TO SUNSHINE HEART C-PULS : Two Down, One To Go
04/27 Genmab's ofatumumab improves survival in leukemia patients in Phase 3 trial
04/27 The Real Value In MabVax May Be Partnerships Rather Than Pipeline


Comments 
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF